Human antibodies fix complement to inhibit plasmodium falciparum invasion of erythrocytes andare associated with protection against malaria

Immunity

Volumn 42, Issue 3, 2015, Pages 580-590

  Boyle, Michelle J ^a,b   Reiling, Linda ^a   Feng, Gaoqian ^a   Langer, Christine ^a   Osier, Faith H ^c   Aspeling Jones, Harvey ^d   Cheng, Yik Sheng ^a,b   Stubbs, Janine ^a   Tetteh, Kevin K A ^d   Conway, David J ^d   McCarthy, James S ^e   Muller, Ivo ^f   Marsh, Kevin ^c   Anders, Robin F ^g   Beeson, James G ^a,h  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g LA TROBE UNIVERSITY   (Australia)

^h MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOGLOBULIN G; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 2, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADAPTIVE IMMUNITY; ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; IMMUNIZATION; LONGITUDINAL STUDY; MALARIA FALCIPARUM; MEROZOITE; NONHUMAN; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL; COMPLEMENT FIXATION TEST; FEMALE; GENE EXPRESSION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MALARIA, FALCIPARUM; MALE; METABOLISM; PARASITEMIA; PARASITOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1Q; COMPLEMENT FIXATION TESTS; COMPLEMENT PATHWAY, CLASSICAL; ERYTHROCYTES; FEMALE; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; MEROZOITES; PARASITEMIA; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS;

EID: 84925004026     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.02.012     Document Type: Article

References (46)

1. Beeson J.G., Fowkes F.J., Reiling L., Osier F.H., Drew D.R., Brown G.V. Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research. Malaria Vaccine Development: Over 40 Years of Trials and Tribulations 2014, 80-104. Future Medicine. G. Corradin, H. Engers (Eds.).
2. Biryukov S., Stoute J.A. Complement activation in malaria: friend or foe?. Trends Mol. Med. 2014, 20:293-301.
3. Blackman M.J., Scott-Finnigan T.J., Shai S., Holder A.A. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J.Exp. Med. 1994, 180:389-393.
4. Boyle M.J., Richards J.S., Gilson P.R., Chai W., Beeson J.G. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood 2010, 115:4559-4568.
5. Boyle M.J., Wilson D.W., Richards J.S., Riglar D.T., Tetteh K.K.A., Conway D.J., Ralph S.A., Baum J., Beeson J.G. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc. Natl. Acad. Sci. USA 2010, 107:14378-14383.
6. Boyle M.J., Langer C., Chan J.A., Hodder A.N., Coppel R.L., Anders R.F., Beeson J.G. Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum. Infect. Immun. 2014, 82:924-936.
7. Cohen S., McGREGOR I.A., Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
8. Courtin D., Oesterholt M., Huismans H., Kusi K., Milet J., Badaut C., Gaye O., Roeffen W., Remarque E.J., Sauerwein R., et al. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS ONE 2009, 4:e7590.
9. Cowan G.J.M., Creasey A.M., Dhanasarnsombut K., Thomas A.W., Remarque E.J., Cavanagh D.R. A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. PLoS ONE 2011, 6:e26616.
10. Crompton P.D., Miura K., Traore B., Kayentao K., Ongoiba A., Weiss G., Doumbo S., Doumtabe D., Kone Y., Huang C.-Y., et al. Invitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect. Immun. 2010, 78:737-745.
11. Dent A.E., Bergmann-Leitner E.S., Wilson D.W., Tisch D.J., Kimmel R., Vulule J., Sumba P.O., Beeson J.G., Angov E., Moormann A.M., Kazura J.W. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS ONE 2008, 3:e3557.
12. Dluzewski A.R., Ling I.T., Hopkins J.M., Grainger M., Margos G., Mitchell G.H., Holder A.A., Bannister L.H. Formation of the food vacuole in Plasmodium falciparum: a potential role for the 19kDa fragment of merozoite surface protein 1 (MSP1(19)). PLoS ONE 2008, 3:e3085.
13. Drew D.R., Hodder A.N., Wilson D.W., Foley M., Mueller I., Siba P.M., Dent A.E., Cowman A.F., Beeson J.G. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS ONE 2012, 7:e51023.
14. Feng J.Q., Mozdzanowska K., Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J.Virol. 2002, 76:1369-1378.
15. Flueck C., Frank G., Smith T., Jafarshad A., Nebie I., Sirima S.B., Olugbile S., Alonso P., Tanner M., Druilhe P., et al. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. Vaccine 2009, 27:2653-2661.
16. Fowkes F.J.I., Richards J.S., Simpson J.A., Beeson J.G. Therelationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med. 2010, 7:e1000218.
17. Galamo C.D., Jafarshad A., Blanc C., Druilhe P. Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition. J.Infect. Dis. 2009, 199:1151-1154.
18. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., Rare L., Baisor M., Lorry K., Brown G.V., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J.Infect. Dis. 2002, 185:820-827.
19. Hessell A.J., Hangartner L., Hunter M., Havenith C.E.G., Beurskens F.J., Bakker J.M., Lanigan C.M.S., Landucci G., Forthal D.N., Parren P.W.H.I., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
20. Hodder A.N., Crewther P.E., Anders R.F. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 2001, 69:3286-3294.
21. John C.C., O'Donnell R.A., Sumba P.O., Moormann A.M., de Koning-Ward T.F., King C.L., Kazura J.W., Crabb B.S. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J.Immunol. 2004, 173:666-672.
22. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6:132-142.
23. Marsh K., Otoo L., Hayes R.J., Carson D.C., Greenwood B.M. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 1989, 83:293-303.
24. McCallum F.J., Persson K.E.M., Mugyenyi C.K., Fowkes F.J.I., Simpson J.A., Richards J.S., Williams T.N., Marsh K., Beeson J.G. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS ONE 2008, 3:e3571.
25. McCarthy J.S., Marjason J., Elliott S., Fahey P., Bang G., Malkin E., Tierney E., Aked-Hurditch H., Adda C., Cross N., et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720. PLoS ONE 2011, 6:e24413.
26. Mehlhop E., Nelson S., Jost C.A., Gorlatov S., Johnson S., Fremont D.H., Diamond M.S., Pierson T.C. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 2009, 6:381-391.
27. Michon P., Cole-Tobian J.L., Dabod E., Schoepflin S., Igu J., Susapu M., Tarongka N., Zimmerman P.A., Reeder J.C., Beeson J.G., et al. The risk of malarial infections and disease in Papua New Guinean children. Am. J. Trop. Med. Hyg. 2007, 76:997-1008.
28. Miura K., Zhou H., Diouf A., Moretz S.E., Fay M.P., Miller L.H., Martin L.B., Pierce M.A., Ellis R.D., Mullen G.E.D., Long C.A. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the invitro growth inhibition assay. Clin. Vaccine Immunol. 2009, 16:963-968.
29. Ndungu F.M., Bull P.C., Ross A., Lowe B.S., Kabiru E., Marsh K. Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol. 2002, 24:77-82.
30. Nebie I., Diarra A., Ouedraogo A., Soulama I., Bougouma E.C., Tiono A.B., Konate A.T., Chilengi R., Theisen M., Dodoo D., et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect. Immun. 2008, 76:759-766.
31. Oeuvray C., Bouharoun-Tayoun H., Gras-Masse H., Bottius E., Kaidoh T., Aikawa M., Filgueira M.C., Tartar A., Druilhe P. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 84:1594-1602.
32. Ogutu B.R., Apollo O.J., McKinney D., Okoth W., Siangla J., Dubovsky F., Tucker K., Waitumbi J.N., Diggs C., Wittes J., et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 2009, 4:e4708. MSP-1 Malaria Vaccine Working Group.
33. Persson K.E.M., Lee C.T., Marsh K., Beeson J.G. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J.Clin. Microbiol. 2006, 44:1665-1673.
34. Polley S.D., Conway D.J., Cavanagh D.R., McBride J.S., Lowe B.S., Williams T.N., Mwangi T.W., Marsh K. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006, 24:4233-4246.
35. Reiling L., Richards J.S., Fowkes F.J.I., Barry A.E., Triglia T., Chokejindachai W., Michon P., Tavul L., Siba P.M., Cowman A.F., et al. Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J.Immunol. 2010, 185:6157-6167.
36. Reiling L., Richards J.S., Fowkes F.J.I., Wilson D.W., Chokejindachai W., Barry A.E., Tham W.-H., Stubbs J., Langer C., Donelson J., et al. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS ONE 2012, 7:e45253.
37. Richards J.S., Stanisic D.I., Fowkes F.J.I., Tavul L., Dabod E., Thompson J.K., Kumar S., Chitnis C.E., Narum D.L., Michon P., et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 2010, 51:e50-e60.
38. Roussilhon C., Oeuvray C., Müller-Graf C., Tall A., Rogier C., Trape J.-F., Theisen M., Balde A., Pérignon J.-L., Druilhe P. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 2007, 4:e320.
39. Shi Y.P., Udhayakumar V., Oloo A.J., Nahlen B.L., Lal A.A. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am. J. Trop. Med. Hyg. 1999, 60:135-141.
40. Silver K.L., Higgins S.J., McDonald C.R., Kain K.C. Complement driven innate immune response to malaria: fuelling severe malarial diseases. Cell. Microbiol. 2010, 12:1036-1045.
41. Sirima S.B., Cousens S., Druilhe P. Protection against malaria by MSP3 candidate vaccine. N.Engl. J. Med. 2011, 365:1062-1064.
42. Stanisic D.I., Richards J.S., McCallum F.J., Michon P., King C.L., Schoepflin S., Gilson P.R., Murphy V.J., Anders R.F., Mueller I., Beeson J.G. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect. Immun. 2009, 77:1165-1174.
43. Stubbs J., Olugbile S., Saidou B., Simpore J., Corradin G., Lanzavecchia A. Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies. Infect. Immun. 2011, 79:1143-1152.
44. Taylor R.R., Allen S.J., Greenwood B.M., Riley E.M. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am. J. Trop. Med. Hyg. 1998, 58:406-413.
45. Wilson D.W., Crabb B.S., Beeson J.G. Development of fluorescent Plasmodium falciparum for invitro growth inhibition assays. Malar. J. 2010, 9:152.
46. Wilson D.W., Fowkes F.J.I., Gilson P.R., Elliott S.R., Tavul L., Michon P., Dabod E., Siba P.M., Mueller I., Crabb B.S., Beeson J.G. Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans. PLoS ONE 2011, 6:e27705.